John Patrick Shannon Jr. - 30 Jan 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Reporting relationship: Chief Executive Officer and Director, Director
Issuer ticker: XERS
Reported as of: 30 Jan 2026
Net transaction value: -$2,506,117
SEC form: 4
Accepted by SEC: 02 Feb 2026, 18:13:18 UTC
Prior SEC filing: 06 Jan 2026
Next SEC filing: 21 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Beth Hecht, Attorney-in-Fact

Key filing fact

John Patrick Shannon Jr. filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 02 Feb 2026.

Key facts

This page summarizes John Patrick Shannon Jr.'s Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Feb 2026, 18:13.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: -$2,506,117.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001553595 Primary reporting owner

Shannon John Patrick Jr

Relationship: Chief Executive Officer and Director, Director
Address: C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO
Signature: /s/ Beth Hecht, Attorney-in-Fact
Signature date: 02 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XERS transaction

Common Stock

Award

Transaction value: $0
Shares: +478,436
Change %: +17%
Price: $0.000000
Shares after: 3,276,083
Date: 30 Jan 2026
Ownership: Direct
Footnotes: F1

XERS transaction

Common Stock

Tax liability

Transaction value: $869,466
Shares: -118,134
Change %: -3.6%
Price: $7.36
Shares after: 3,157,949
Date: 31 Jan 2026
Ownership: Direct
Footnotes: F2

XERS transaction

Common Stock

Tax liability

Transaction value: $821,531
Shares: -111,621
Change %: -3.5%
Price: $7.36
Shares after: 3,046,328
Date: 31 Jan 2026
Ownership: Direct
Footnotes: F2

XERS transaction

Common Stock

Tax liability

Transaction value: $815,120
Shares: -110,750
Change %: -3.6%
Price: $7.36
Shares after: 2,935,578
Date: 31 Jan 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XERS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +639,639
Change %
Price: $0.000000
Shares after: 639,639
Date: 30 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 639,639
Exercise price: $7.36
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.

Footnote F2

Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026.

Footnote F3

These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

SEC remarks

Chief Executive Officer and Director